Some stockholders of Endo International plc (NASDAQ:$ENDP) are probably having a good week, as the stock’s “hold” rating was reaffirmed by analysts at Oppenheimer Holdings, Inc. Investors were informed on Thursday of this affirmation through a research note issued by Oppenheimer.
However, not everything can be as it seems. A number of research reports on Endo International has left investors in a haze, deciding whether the company’s stocks are of “buy” rating or “hold” rating. On Tuesday, February 28, 2017, Guggenheim reissued a “buy” rating on the company’s shares, and issued a $35.00 target price. Then, just two weeks later, Canaccord Genuity gave the company a “hold” rating in a research report on Tuesday, March 14th, with a $14.00 target price on its shares. JMP Securities, however, set a $20.00 price target on Endo’s shares, reaffirming an “outperform” rating on Wednesday, March 15th. Meanwhile, Mizuho had increased Endo’s target price to $17.00 on Friday, March 3rd. Finally, on Wednesday, May 17th Vetr set a “sell” rating on Endo’s stocks and set the price target at $11.34.
Currently, the consensus rating for Endo International plc’s stock is “Hold”, and the price target is $19.40. On Thursday, June 9th, Endo’s share price opened at $13.78. The company currently has a market cap of $3.07 billion, with a one year low of $9.70 and a one year high of $24.93. The stock’s 50-day moving average is $12.13, and the 200-day moving average is $12.96.
In its quarterly earnings data that was released on Tuesday, May 9th, Endo reported $1.23 earnings per share, a positive 15.95% return on equity, a 3.32% negative net margin, and a revenue of $1.04 billion. Its earnings per share beat Thomson Reuters’ projection of $1.10, while its revenue beat the expected $1.02 billion projected by various analysts. On a year-over-year basis, Endo’s revenue went up 7.7%. For the current fiscal year, analysts are now predicting a $3.61 earnings per share for the company.
With good numbers from last quarter, some large investors have recently bought and sold shares of the company. Amalgamated Banks increased its shares by 2.0%, now owning 32,357 shares of the company’s stock after purchasing another additional 619 shares in the last quarter. The stock is worth $361,000. Meanwhile, Gamco Investors INC. ET AL (NYSE:$GBL) increased its position in Endo by 1.7%. They now own 47,500 shares of Endo, worth $782,000, after purchasing another 800 shares last quarter. After increasing its position in Endo by 12.3%, Point View Wealth Management Inc. now owns 11,431 shares of Endo’s stock after buying another additional 1,254 shares last quarter. The total worth of the stock is now $128,000. Jensen Investment Management Inc. increased ownership of Endo by 5.8%, now owning 24,660 shares after purchasing an additional 1,360 shares in the last quarter. The total worth of the stock is $275,000.
The biggest ownership increase came from Macquarie Group Ltd (ASX:$MQG), who increased its position in Endo by 132.1%. Macquarie now owns 6,500 shares of Endo’s stock after buying additional 3,700 shares in the last quarter. The total shares is worth $107,000.
About 95.50% of Endo’s stock is owned by institutional investors and hedge funds.
Featured Image: Fiercepharma.com
